SOPHiA GENETICS (NASDAQ:SOPH) Posts Earnings Results, Hits Expectations

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) released its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23), Zacks reports. The firm had revenue of $17.73 million during the quarter, compared to analysts' expectations of $17.71 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Stock Up 4.2 %

SOPHiA GENETICS stock traded up $0.13 during midday trading on Friday, reaching $3.24. The company's stock had a trading volume of 50,808 shares, compared to its average volume of 69,890. The company has a market cap of $211.82 million, a P/E ratio of -2.97 and a beta of 1.01. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. The business has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $3.55. SOPHiA GENETICS has a fifty-two week low of $2.70 and a fifty-two week high of $6.28.

Analysts Set New Price Targets

Separately, Craig Hallum began coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a "buy" rating and a $11.00 target price on the stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.